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A B S T R A C T
Purpose: There is relatively little known about the effects of new antiepileptic drugs (AEDs) on sleep. This
study was done to evaluate the effect of levetiracetam (LEV) on subjective sleep quality and sleep
architecture in patients with epilepsy, and the results were comparedwith the effects of carbamazepine-
CR (CBZ-CR).
Methods: This is a longitudinal randomized controlled trial using two different treatments, LEV
(1000 mg/day) or CBZ-CR (400 mg/day). Thirty-one subjects (16 LEV and 15 CBZ-CR) had partial epilepsy
and were tested with an overnight polysomnography (PSG) with full 10–20 electrodes. Sleep
questionnaires and National Hospital Seizure severity Scale (NHS3) were evaluated. PSG and the
questionnaires were repeated after 4–6 weeks of treatment.
Results: In the LEV group, when treatment PSG ﬁndings were compared with baseline, there was a
signiﬁcant increase in sleep efﬁciency (p = 0.039) but no changes in subjective sleep parameters. In the
CBZ-CR group, there was a signiﬁcant increase in the percentage of slow wave sleep (p = 0.038) while
other sleep parameters were not signiﬁcantly changed after treatment. There were no signiﬁcant
differences in effects on sleep between the LEV and CBZ-CR groups.
Conclusion: LEV may increase sleep efﬁciency without major effects on sleep structure with an overall
effect on sleep parameters comparable to CBZ-CR.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Patients with epilepsy often suffer from inadequate or
ineffective sleep.1,2 Seizures themselves can disrupt sleep, even
when they occur during wakefulness.1 Impaired sleep can cause
considerable impairment of daytime functioning and quality of
life.3–5 In patients with epilepsy, inadequate sleep can induce
daytime drowsiness and memory dysfunction, and can also
contribute to intractable seizures.4 Prolonged impaired sleep
may causemore severe seizures and intractability in some patients
with epilepsy.4,6
Antiepileptic drugs (AEDs) have also been found to disrupt
sleep and cause daytime drowsiness.4,7–10 However, the effects of
AEDs are variable and often difﬁcult to distinguish from the effects* Corresponding author at: Department of Neurology, Dongsan Medical Center,
Keimyung University School of Medicine, 194 Dongsan-dong, Jung-gu, Daegu 700-
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.006of improved seizure control. Older generation AEDs typically
reduce the percentage of rapid eye movement (REM) sleep and
slow wave sleep (SWS), increase fragmentation, and induce
daytime sleepiness except for carbamazepine that may increase
SWS.8,11–14 There is relatively little known about the effects of the
new AEDs on sleep.
Levetiracetam (LEV) is a new generation AED used to treat both
partial and generalized epilepsy. Its pharmacodynamics is not
clearly known, but appears to be distinct from that of classic AEDs
and unrelated to voltage-gated sodium channels, gamma-amino-
butyric acid (GABA)- or glutamate-mediated synaptic transmis-
sion.15,16 There have been few reports about the effects of LEV on
sleep. A few studies have shown that LEV does affect some
elements of subjective sleep perception in healthy volunteers and
patientswith partial epilepsy but has no affect on sleep structure in
normal volunteers.17–19
This study was done to evaluate the effects of LEV on subjective
sleep quality and sleep structures in patients with partial epilepsy,
and the results were compared with the effect of carbamazepine-
CR (CBZ-CR) in patients with partial epilepsy.vier Ltd. All rights reserved.
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The study was of a longitudinal randomized controlled trial
using two different treatment regimens i.e., LEV (1000 mg/day) or
CBZ-CR (400 mg/day). All participating patients were newly
diagnosed partial epilepsy patients who had their ﬁrst seizure
between six and onemonth prior to entry into the study. Diagnoses
of epilepsy and seizure type were based on history, clinical
presentation, EEG or video-EEG monitoring ﬁndings, and neuro-
imaging. Patients with primary generalized epilepsy, as evidenced
by EEG ﬁndings, were excluded. The study was approved by the
Institutional Ethics Committee.
None of the patients had taken any other AEDs prior to the
study. Patients with sleep problems were excluded from the study
based on history, standard sleep questionnaires, screening for a
stable sleep–wake routine, and overnight polysomnography (PSG).
Subjects who had a seizure the day prior to- or during the PSG,
excessive caffeine consumption (deﬁned as more than 2 cups a
day), alcohol abuse, illicit drugs, and psychoactive medications
were excluded as well. The subjects did not report any signiﬁcant
change in their life style or routine daily activities during the study
period. Thirty-six patients were enrolled of whom 5were excluded
due to poor compliance with medication or sleep studies, or they
were lost to follow-up. Thirty-one patients completed the study
(16 LEV and 15 CBZ-CR). Seven patients had temporal lobe-, 11
patients had frontal lobe-, and 5 patients had parietal lobe
epilepsy. In 8 patients the seizure focus was unknown. The mean
ages of LEV and CBZ-CR groups were 31  15.31 and 29  9.31,
respectively. The dose for LEV was targeted at a maintenance dose of
1000 mg/day, and the dose for CBZ-CRwas targeted at a maintenance
dose of 400 mg/day. All subjects who remained on medication were
able to tolerate the target dosages at least a month before their follow
up sleep study. An overnight PSG using standard PSG electrodes
including full 10–20 EEG electrode system, EMG, EOG, piezoelec-
trodes and nasal thermocouples (Grass Telefactor Technologies, RI,
USA) was performed on each patient before and after treatment with
each drug (weeks 4–6). Additionally, sleep questionnaires and
National Hospital Seizure Severity Scale (NHS3)20 were used each
time after each PSG andwe checked for any seizures or adverse eventsTable 1
Summary of the characteristics and sleep parameters of the LEV group and the CBZ gr
LEV (n=16)
Age (year) 31.4415.31 (15–66)
Gender (men/women) 11 (68.8%)/5 (31.3%)
Caffeine (+) 13 (81.3%)
Alcohol (+) 3 (18.8%)
Smoking (+) 5 (31.3%)
Exercise (+) 4 (25.0%)
BMI 22.822.92 (17.8–26.6)
BDI-2 8.945.62 (2–25)
HAS 5.752.54 (1–10)
NHS3 9.694.42 (0–18)
Sleep parameters
PSQI 4.693.28 (1–15)
KESS 5.254.27 (0–18)
Polysomnography
Sleep latency 12.2514.55 (0.5–58.0)
REM latency 132.6668.37 (52–287.5)
Total sleep time 383.3665.13 (200.5–477.9)
Sleep efﬁciency 84.3213.65 (45.59–99.3)
Stage N1% 9.924.22 (3.10–19.5)
Stage N2% 51.388.34 (35–67.5)
Stage N3% 19.947.79 (9.80–40.3)
REM% 18.744.48 (13.1–25.9)
Arousal index 7.093.91 (2.9–16.3)
WASO 55.6156.06 (2.5–218)
NHS3, National Hospital Seizure Severity Scale; PSQI, Pittsburgh Sleep Quality Index; KE
Beck Depression Inventory-2; WASO, Wake time After Sleep Onset.during follow-up visits. Sleep questionnaires were composed of sleep
diaries, the Pittsburg Sleep Quality Index (PSQI),21 the Korean version
of the Epworth Sleepiness Scale (KESS),22 Beck’s depression invento-
ry-2 (BDI-2) and the Hospital Anxiety Scale (HAS).23 All PSG and
questionnaires were repeated after 4–6 weeks of treatment. The PSGs
were scored by a sleep technician using standard scoring procedures
according to the 2007 edition of the AASM Manual for the Scoring of
Sleep and Associated Events24 and interpreted by a sleep medicine-
certiﬁed physician who was blind to treatment. Variables studied in
the PSGs included sleep latency, REM sleep latency, total sleep time,
sleep efﬁciency, percentage of each sleep stage, arousal index, and
Wake time After Sleep Onset (WASO). Sleep latency, sleep efﬁciency,
and total sleep time were considered as the primary outcome
measures and the rest of the objective parameters and all of the
subjective parameters were considered as secondary outcome
measures.
Using ana level of 0.05 and power of 80%, a sample size of 13 for
each group was needed to detect a difference between groups.
Assuming a dropout rate of 15%, a sample of at least 31 subjects
was selected. Demographic data between two groups were
compared by independent student’s t-test and x2-test. Repeated
measures analysis of variance (ANOVA) test was performed on the
change of sleep parameters from baseline. To compare the sleep
effects of two groups at the same time, independent student’s t-
test was used. Differences were considered signiﬁcant when p-
value < 0.05. Statistical analysis was done on SPSS ver. 17.0.
3. Results
3.1. Clinical and demographic characteristics
Thirty-one patients with partial epilepsy completed the study
(16 LEV, 15 CBZ-CR). The baseline PSG did not reveal any signiﬁcant
sleep disordered breathing, periodic limb movement of sleep,
insomnia or sleep related movement disorders. There were no
signiﬁcant differences between the LEV and CBZ-CR groups with
respect to age, sex, caffeine and alcohol consumption, BMI, and
seizure frequency, nor were there any signiﬁcant differences in
sleep characteristics including sleep onset latency, sleep efﬁciency,oup in baseline state.
CBZ (n=15) p
29.809.31 (15–49) 0.724
11 (73.3%)/4 (26.7%) 0.779
12 (80.0%) 1.000
7 (46.7%) 0.135
5 (33.3%) 1.000
3 (20.0%) 1.000
22.252.60 (17.7–27.6) 0.436
11.425.71 (0–19) 0.235
7.953.15 (2–13) 0.042
7.474.31 (0– 13) 0.168
4.671.84 (1–7) 0.983
4.942.80 (1–10) 0.849
13.9317.74 (0.5–66.0) 0.774
115.6075.38 (61–353.5) 0.514
395.8356.01 (266.5–459.6) 0.573
86.9811.54 (59.8–98.3) 0.565
10.393.72 (4.60–18.9) 0.743
49.197.44 (39.5–59.8) 0.448
21.299.76 (8.2–47.1) 0.674
19.156.22 (3.7–25.8) 0.837
8.494.32 (4.3–18.2) 0.351
37.9733.46 (7–111) 0.300
SS, Korean version of Epworth Sleepiness Scale; HAS, Hospital Anxiety Scale; BDI-2,
Table 2
Comparison of the effects on sleep in the levetiracetam treatment group.
Clinical and sleep parameters Levetiracetam (n=16)
Baseline After treatment p
NHS3 9.694.42 1.251.92 0.001
Hospital Anxiety Scale 5.752.54 4.063.15 0.005
BDI-2 8.945.62 6.944.61 0.023
PSQI 4.693.28 4.311.99 1.000
KESS 5.254.27 4.383.52 0.16
Polysomnographic ﬁndings
Total sleep time 383.3665.13 409.9648.02 0.074
Sleep latency 12.2514.55 7.9410.84 0.099
REM latency 132.6668.37 128.0977.91 0.756
Sleep efﬁciency 84.3213.65 90.624.77* 0.039
WASO 55.6156.06 31.7238.88* 0.047
Stage N1% 9.924.22 9.415.09 0.724
Stage N2% 51.388.34 49.987.70 0.540
Stage N3% 19.947.79 22.318.03 0.302
Stage REM% 18.744.48 18.314.07 0.763
Arousal index 7.093.91 6.995.14 0.717
NHS3, National Hospital Seizure Severity Scale; BDI-2, Beck Depression Inventory-
2; PSQI, Pittsburgh Sleep Quality Index; KESS, Korean version of Epworth Sleepiness
Scale; WASO, Wake time After Sleep Onset.
* Signiﬁcant difference within the group (p<0.05).
[()TD$FIG]
Fig. 1. Effects of levetiracetam on sleep efﬁciency. *Signiﬁcant difference within
baseline and after treatment (p < 0.05).
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differences in seizure severity using the NHS3 between baseline
and treatment revealed a signiﬁcant improvement in both groups
(p = 0.001). After treatment in both groups, the HAS and BDI-2
showed a signiﬁcant improvement (p < 0.05) (Table 1).
3.2. Subjective measures
Analysis of the sleep questionnaires showed no signiﬁcant
difference between baseline and post-treatment between the two
groups, although there was a trend for a decrease in PSQI with CBZ
(Tables 2 and 3).
3.3. Objective measures
In the LEV group, when post-treatment PSG ﬁndings were
comparedwith baseline, therewas a signiﬁcant increase in decrease
in theWASO (p = 0.047) and sleep efﬁciency (p = 0.039) (Table 2 and
Fig. 1). However, there were no signiﬁcant differences in total sleep
time, sleep latency, REM latency, or percentages of sleep stages. In
the CBZ-CR group, therewere signiﬁcant increases in the percentageTable 3
Comparison of the effects on sleep in the carbamazepine-CR treatment group.
Clinical and sleep parameters Carbamazepine-CR (n=15)
Baseline After treatment p
NHS3 7.474.31 1.072.55 0.001
Hospital Anxiety Scale 7.953.15 5.353.56 0.002
Beck Depression Inventory-2 11.425.71 9.454.81 0.037
PSQI 4.671.84 3.801.94 0.077
KESS 4.942.80 5.674.55 0.362
Polysomnographic ﬁndings
Total sleep time 395.8356.01 410.8538.32 0.331
Sleep latency 13.9317.74 9.8710.20 0.733
REM latency 115.6075.38 93.2353.20 0.233
Sleep efﬁciency 86.9811.54 89.297.10 0.46
WASO 37.9733.46 29.4327.15 0.061
Stage N1% 10.393.72 9.424.92 0.191
Stage N2% 49.197.44 44.818.66 0.074
Stage N3% 21.299.76 26.789.47* 0.038
Stage REM% 19.156.22 18.993.81 0.394
Arousal index 8.494.32 8.564.93 0.842
NHS3, National Hospital Seizure Severity Scale; PSQI, Pittsburgh Sleep Quality
Index; KESS, Korean version of Epworth Sleepiness Scale; WASO, Wake time After
Sleep Onset.
* Signiﬁcant difference within the group (p<0.05).of slow wave sleep (p = 0.038) while other sleep parameters were
not signiﬁcantly changed after treatment (Table 3).
The overall effect on seizure reduction and sleep parameters of
LEV was comparable to CBZ-CR, although there were some
differences in the effects on individuals.
4. Discussion
These results suggest that in addition to its antiepileptic effects
in patients with partial epilepsy, LEV stabilizes sleep and does not
affect daytime sleepiness, as demonstrated by the signiﬁcant
increase in sleep efﬁciency, and no signiﬁcant effect on subjective
sleep parameters. Our results differwith some of the ﬁndings of the
few available studies.17,18 Bell et al.17 have reported increased
stage 2, decreased stage 4, and improved subjective sleep
parameters with no change in objective measures of sleep
continuity. These ﬁndings were seen in 17 patients with partial
epilepsy treated with CBZ and LEV in a double-blind crossover
placebo-controlled study compared to healthy controls. The same
study also reported increased SWS, stage 2 sleep and REM latencies
with CBZ. The fact that their patients were not treatment naive as
in our study, as well as its crossover design might explain different
results. The increase in the percentage of slow wave sleep in the
CBZ group was similar to our ﬁnding. Bazil et al.18 reported that
LEV increased the number of awakenings with no other changes in
any of the objective measures; however this study used only
healthy volunteers.
Decrease in WASO was accompanied by improvement of sleep
efﬁciency, although the percentage of NREM and REM sleep were
unchanged. We considered the possibility that the decrease in
WASO or increase in sleep efﬁciency could be due to seizure
reduction, rather than a direct effect of LEV. Although the CBZ-CR
group also had reduced seizure frequency, they did not share the
same beneﬁcial effects on sleep with the LEV group. Therefore, it
may be presumed that LEV per se may increase sleep efﬁciency.
The physiological mechanisms for these effects remain unknown.
Although somnolence is known as a potential adverse effect of
LEV,25,26 our study showed that LEV did not increase daytime
sleepiness throughout the KESS questionnaire in consistence with
a prior report.19 Therefore, further studies will be needed to clarify
LEV’s effect on sleepiness through objectivemeasurements such as
multiple sleep latency tests.
CBZ has been reported to improve sleep stability.10 The effects
of CBZ on sleep include improvement in sleep continuity, increase
in total sleep time, decrease in REM sleep density, unchanged REM
latency and percentage of REM sleep, and shortening of latency to
sleep onset.2,7,8,10 Our data showed that epilepsy patients on CBZ-
Y.W. Cho et al. / Seizure 20 (2011) 336–339 339CR had an increase in SWS compared with the baseline phase
consistent with previous published studies.27 However, the effects
of CBZ on REM sleep architecture were not observed in our study.
Gigli et al. showed that REM sleep was reduced in patients with
temporal lobe epilepsy and in seizure-free controls after acute
administration of CBZ.28 These effects were less pronounced after
prolonged CBZ treatment.8 Chronic CBZ-CR treatment did not
signiﬁcantly modify nocturnal sleep or daytime somnolence. Our
study also shows similar results.
One limitation of our study might be the fact that the seizure
focus in eight patients could not be conﬁrmed by invasive
recordings as it deemed clinically unnecessary. Also, the sleep
studies were done in a sleep laboratory, whichmay have had some
inﬂuence on the sleep quality. However, this is in consistence with
the current standards of practice and there were no inter-subject
variability in terms of studymethods. Also, the dosages used in our
patients were relatively low therapeutic doses and might not
represent the effects of higher dosages. Further studies comparing
different dosages might be needed to address this issue.
Despite signiﬁcant individual differences in the effects of the
two drugs, as for the two groups overall, the effects of LEV on sleep
in patients with partial epilepsy were comparable to those of CBZ.
Many epilepsy patients have sleep disturbances which would
have a negative effect on seizure control. Therefore, in choosing
AEDs, one should consider the sleep effect of each AED.
5. Conclusion
These ﬁndings suggest that LEV may increase sleep efﬁciency
without major effects on sleep structure or subjective sleep
measures and an overall comparable effect to CBZ-CR.
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